Amgen’s Phase 3 DeLLphi-305 trial shows the IMDELLTRA Imfinzi combination delivers a statistically significant, clinically meaningful overall survival benefit as first-line maintenance therapy in extensive-stage small cell lung cancer, alongside gains in progression-free survival and response rate.
Novo Nordisk’s phase 3 STEP Young trial found that 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, versus none on placebo — a first efficacy readout for semaglutide in this young age group.
Novartis announced pelacarsen Lp(a)HORIZON trial results on September 4, 2026, revealing that the Phase III cardiovascular outcomes study did not meet its primary endpoint, even though the investigational therapy lowered Lp(a) levels in more than 8,300 patients with established cardiovascular disease.
AbbVie’s Phase 3 CERVINO trial shows etentamig, an investigational BCMA x CD3 bispecific, significantly improved response rate and progression-free survival versus standard therapies in relapsed/refractory multiple myeloma.
Amgen and AstraZeneca announced that TEZSPIRE (tezepelumab-ekko) achieved statistically significant and clinically meaningful results across both co-primary endpoints and all key secondary endpoints in the Phase 3 CROSSING trial in eosinophilic esophagitis, with benefits sustained through week 52.
AstraZeneca has officially stopped its Phase III eVOLVE-Lung02 trial evaluating volrustomig plus chemotherapy in first-line metastatic NSCLC following a recommendation from the Independent Data Monitoring Committee.
Novo Nordisk has released headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating monthly subcutaneous ziltivekimab in patients with ASCVD, CKD, and elevated systemic inflammation.
Roche’s next-generation KRAS G12C inhibitor, divarasib, has achieved statistical significance in a global head-to-head Phase III trial against sotorasib and adagrasib for advanced non-small cell lung cancer.
BridgeBio Pharma and Kyowa Kirin announced the publication of positive data from the global Phase 3 PROPEL 3 study of oral infigratinib for pediatric achondroplasia in The New England Journal of Medicine (NEJM), demonstrating unparalleled improvements in annualized height velocity and body proportionality.
Eli Lilly and Company announced results from its Phase 3 BRUIN CLL-322 trial, demonstrating that adding Jaypirca to a venetoclax time-limited regimen cuts the risk of disease progression or death by 45% in previously treated CLL/SLL patients.
